New insulin injection into the belly could speed up diabetes treatment

NCT ID NCT07341373

Recruiting now Knowledge-focused Sponsor: Portal Diabetes, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new insulin formula (U-500) given directly into the belly cavity in 25 adults with type 1 diabetes. Researchers want to see if it's safe, how fast it's absorbed, and how quickly it works compared to standard insulin shots. Participants will have their blood sugar kept stable for 12 hours after a single dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Portal Insulin U-500 (PI-U500)
What this could lead to: If successful, this could lead to a faster-acting insulin delivery method for people with type 1 diabetes, potentially improving blood sugar control.
What could go wrong: This is an early Phase 1 safety study with only 25 participants, so results may not apply broadly. The intraperitoneal route carries risks like infection or pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Insulin Resistance type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES

Contacts and locations

Locations

ProSciento, Inc.
RECRUITING

Chula Vista, California, 91911, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.